Article
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.
European journal of gastroenterology & hepatology - 1 Nov 2004
Thabut Dominique, Thibault Vincent, Bernard-Chabert Brigitte, Mouquet Catherine, Di Martino Vincent, Le Calvez Sophie, Opolon Pierre, Benhamou Yves, Bitker Marc Olivier, Poynard Thierry
Abstract excerpt
BACKGROUND: Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication. As other available HBV therapies, its efficacy is hampered by relapse after discontinuation and by the risk of viral breakthrough. A recent study suggests that pre-emptive lamivudine therapy improves survival in HBV renal transplants, but few data are available regarding its long-term use in this population. The clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.